Hutchison China MediTech Limited Share Price Today: Live Updates & Key Insights
Hutchison China MediTech Limited share price today is $11.035, up 0.46%. The stock opened at $10.935 against the previous close of $10.96, with an intraday high of $11.11 and low of $10.93.
Hutchison China MediTech Limited Share Price Chart
Hutchison China MediTech Limited
Hutchison China MediTech Limited Share Price Performance
Hutchison China MediTech Limited Institutional Holdings
Hutchison China MediTech Limited Market Status
Hutchison China MediTech Limited Fundamentals
Market Cap 1884.58 M
PB Ratio 1.5529
PE Ratio 4.1832
Enterprise Value 626.88 M
Total Assets 1753.10 M
Volume 50650
Hutchison China MediTech Limited Company Financials
About Hutchison China MediTech Limited & investment objective
Company Information HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Organisation Drug Manufacturers - Specialty & Generic
Employees 1796
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. Wei-Guo Su B.Sc., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Hutchison China MediTech Limited FAQs
What is the share price of Hutchison China MediTech Limited today?
The current share price of Hutchison China MediTech Limited is $11.035.
Can I buy Hutchison China MediTech Limited shares in India?
Yes, Indian investors can buy Hutchison China MediTech Limited shares by opening an international trading and demat account with Motilal Oswal.
How to buy Hutchison China MediTech Limited shares in India?
You can easily invest in Hutchison China MediTech Limited shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Hutchison China MediTech Limited shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Hutchison China MediTech Limited.
Can I buy fractional shares of Hutchison China MediTech Limited?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Hutchison China MediTech Limited?
Hutchison China MediTech Limited has a market cap of $1884.58 M.
In which sector does Hutchison China MediTech Limited belong?
Hutchison China MediTech Limited operates in the Drug Manufacturers - Specialty & Generic sector.
What documents are required to invest in Hutchison China MediTech Limited stocks?
To invest, you typically need:
What is the PE and PB ratio of Hutchison China MediTech Limited?
The PE ratio of Hutchison China MediTech Limited is 4.18 and the PB ratio is 1.55.